Login to Your Account

Orexigen, Vivus Also Take a Hit

Arena's Weight Loss Drug has 'Slim' Efficacy, Safety Concerns

By Donna Young

Wednesday, September 15, 2010
WASHINGTON – Arena Pharmaceuticals Inc.'s shares (Nasdaq:ARNA) nose dived 39.7 percent Tuesday after FDA reviewers said they could not definitively conclude that the firm's experimental weight loss drug lorcaserin was devoid of valvulopathy-related cardiac effects.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription